Page 177 - Binder2

Let’s break down what that makes possible.

Low-Cost Scalability

In conventional systems, scaling means bigger
infrastructure. Larger bioreactors. More purification units.
Higher upfront capital and long-term operational expense.
And even with scale, unit economics rarely shift
dramatically—the inputs are costly and the footprint is
fixed.

In contrast, plant-based production scales horizontally and
affordably. A few square meters of greenhouse or
hydroponic bed can produce grams of therapeutic
protein—enough for thousands of doses—without the
overhead of industrial fermentation. No bioreactors. No
stainless steel tanks. No proprietary cell lines with tightly
guarded patents.

Just:

• Sunlight
• Water
• Soil or hydroponic substrate
• A gene cassette inserted into the right plant
compartment

And once established, the system is modular. You can add
trays. Stack grow beds. Expand to new geographies. It’s not
“scale-up”—it’s scale-out, and it enables a cost-per-dose
that drops by orders of magnitude compared to
traditional biologics.

175